PT1146896E - Formulacoes monodispersas de analogo acilado e hexamerico insulina - Google Patents

Formulacoes monodispersas de analogo acilado e hexamerico insulina

Info

Publication number
PT1146896E
PT1146896E PT00904496T PT00904496T PT1146896E PT 1146896 E PT1146896 E PT 1146896E PT 00904496 T PT00904496 T PT 00904496T PT 00904496 T PT00904496 T PT 00904496T PT 1146896 E PT1146896 E PT 1146896E
Authority
PT
Portugal
Prior art keywords
formulations
human insulin
modified
acylated
monodispersas
Prior art date
Application number
PT00904496T
Other languages
English (en)
Inventor
Kingman Ng
Shun Li
Eric Alan Watts
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT1146896E publication Critical patent/PT1146896E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT00904496T 1999-01-26 2000-01-26 Formulacoes monodispersas de analogo acilado e hexamerico insulina PT1146896E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11729199P 1999-01-26 1999-01-26

Publications (1)

Publication Number Publication Date
PT1146896E true PT1146896E (pt) 2002-10-31

Family

ID=22372048

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00904496T PT1146896E (pt) 1999-01-26 2000-01-26 Formulacoes monodispersas de analogo acilado e hexamerico insulina

Country Status (9)

Country Link
EP (1) EP1146896B1 (pt)
JP (1) JP2002535287A (pt)
AT (1) ATE220917T1 (pt)
AU (1) AU2624400A (pt)
DE (1) DE60000288T2 (pt)
DK (1) DK1146896T3 (pt)
ES (1) ES2180511T3 (pt)
PT (1) PT1146896E (pt)
WO (1) WO2000043034A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
AU2003218635A1 (en) * 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
DE60335797D1 (de) 2002-05-07 2011-03-03 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
BR0316560A (pt) 2002-11-26 2005-10-04 Nobex Corp Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto
PL1773878T3 (pl) * 2004-07-19 2015-07-31 Biocon Ltd Koniugaty insulina-oligomer, ich formulacje i zastosowania
EP2505593A1 (en) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
WO2008015099A2 (en) 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
PL2910570T3 (pl) 2008-03-18 2017-06-30 Novo Nordisk A/S Stabilizowane względem proteaz, acylowane analogi insuliny
EP2352513B1 (en) 2008-10-30 2016-09-14 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
ES2670969T3 (es) 2012-11-13 2018-06-04 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
MX366636B (es) 2013-10-07 2019-07-17 Novo Nordisk As Nuevo derivado de un análogo de insulina.
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
RU2758367C2 (ru) 2016-12-16 2021-10-28 Ново Нордиск А/С Фармацевтические композиции, содержащие инсулин
AU2018275545B2 (en) 2017-06-01 2021-02-04 Eli Lilly And Company Rapid-acting insulin compositions
AU2018317810A1 (en) 2017-08-17 2020-03-19 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2021033066A1 (en) * 2019-08-16 2021-02-25 Lamark Biotech Pvt Limited A formulation of insulin based on crystal-seeding in hydrogels and method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1120019C (zh) * 1996-06-20 2003-09-03 诺沃挪第克公司 含NaCl的胰岛素制品
DE69829953T2 (de) * 1997-02-07 2006-03-02 Novo Nordisk A/S Kristallisation von proteinen
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions

Also Published As

Publication number Publication date
EP1146896A2 (en) 2001-10-24
ATE220917T1 (de) 2002-08-15
DE60000288T2 (de) 2003-01-16
DK1146896T3 (da) 2002-09-02
JP2002535287A (ja) 2002-10-22
WO2000043034A3 (en) 2000-12-28
WO2000043034A2 (en) 2000-07-27
ES2180511T3 (es) 2003-02-16
EP1146896B1 (en) 2002-07-24
DE60000288D1 (de) 2002-08-29
AU2624400A (en) 2000-08-07

Similar Documents

Publication Publication Date Title
PT1146896E (pt) Formulacoes monodispersas de analogo acilado e hexamerico insulina
AU582920B2 (en) Continuous release pharmaceutical compositions
WO2002043750A3 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
EP1234586A3 (en) Hepatoselective pharmaceutical actives
EP1808438A3 (en) Purification and stabilization of peptide and proteins in pharmaceutical agents
EP2308963A3 (en) System for processing lipoaspirate cells
BR9607647A (pt) Derivado de insulina e composição farmacêutica e processo para o tratamento de diabetes em um paciente em necessidade deste tratamento
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
ATE107514T1 (de) Stabilisierte protein- oder peptidkonjugate.
DK0969843T3 (da) Antitussive formuleringer indeholdende theobromin
IL207923A0 (en) Metal-binding compounds and uses therefor
BR9811755A (pt) Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica
HK1046242A1 (en) Preparations for the application of anti-inflammatory agents.
CA2522146A1 (en) Uptake of macromolecules
WO1996032134A3 (de) Konjugat aus einem wirkstoff, einem polyether und ggf. einem nicht als körperfremd angesehenen, nativen protein
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
Yaegaki et al. The effect of mouthwash on oral malodour production
WO2001045714A3 (en) Formulations of adenosine a1 agonists
MD950010A (ro) Compoziţie pentru înlăturarea sau dezactivarea componentelor dăunătoare în sînge sau alte lichide extracelulare ale organismului şi procedeu de obţinere
PT97878A (pt) Processo para a preparacao de uma composicao farmaceutica para uso oftalmico contendo hexetidina ou seus derivados ou sais
UA28283A (uk) Природний лікувальний засіб
MX9704388A (es) Incremento de la concentracion de creatina y glicogeno en musculos.
UA37377A (uk) Спосіб отримання мазі для лікування захворювань, які викликані внутрішньоклітинними інфекційними агентами
MX9800126A (es) Utilizacion en una composicion de un extracto de al menos una labiada.